Mar 02, 2020 / 04:20PM GMT
Kenneth Charles Cacciatore - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
(technical difficulty)
a $23 price target. Our legal consultants believe you're going to defend the patents, and our consultants tell us you're going to sell a lot of drug. So we believe both those 2 things. Let me turn it over to John Thero and Elisabeth. Thanks for helping set this up. So I'll turn it over to John.
John F. Thero - Amarin Corporation plc - President, CEO & Director
Ken, thanks for that introduction. Thanks for the coverage. We look forward to trying to make you a hero while making money for investors along the way. I am here to talk about Amarin. Amarin, if you don't know us, we're leading a new paradigm in cardiovascular health. I think you probably -- if you do know us, you've seen accolades for our science. You're probably also aware that we're the fastest-growing cardiovascular drug in the market these days. And if you're not looking at us from an investment perspective, the American Heart Association predicts that in about
Amarin Corporation PLC at Cowen HealthCare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers